Individually manufacturing these treatments is already happening and will be very expensive. For example, we already have FDA approved blood cancer treatments involving harvesting each patient's own cells in a lab and then adding a gene to it and now it is CAR-T cells to be given back to the specific patient. Brain cancer patients are in clinical trials for CAR-T. An AI would help to develop the CAR-T for each person. Regarding money, that is where the health insurance comes in. This is very expensive. The cost of CAR-T can exceed $500,000 to $1M per patient.
What's the percentage of remission?
The test subjects are still very new but the scientists are excited to report "complete response (CR) rates of 40–54%, 67% and 69–74% were observed in patients with R/R aggressive B cell lymphomas" (that's just one type of cancer subjects)
https://pmc.ncbi.nlm.nih.gov/articles/PMC10100620/ "Long-term outcomes following CAR T cell therapy: what we know so far"
There are other CARs that are in experiments genetically engineering a patient's cells.
This is where the research money is going, and this is going to hit insurance companies when approved.
Thanks for the detailed reply!